Moderna announced on Wednesday that it is set to begin testing a new version of its COVID-19 vaccine that was specifically designed to target an emerging variant of the coronavirus that was first reported in South Africa, NBC News reported.
The company said that it has shipped doses of its variant-specific booster shot to the US National Institutes of Health for clinical trials. This development is part of Moderna's efforts to counter strains of the coronavirus that are circulating and to get ahead of the constantly mutating virus.
Read more